RT Journal Article
SR Electronic
T1 Side effect profile and comparative tolerability of 21 antidepressants in the acute treatment of major depression in adults: protocol for a network meta-analysis
JF Evidence Based Mental Health
JO Evid Based Ment Health
FD BMJ Publishing Group Ltd, Royal College of Psychiatrists and British Psychological Society
SP 61
OP 66
DO 10.1136/ebmental-2019-300087
VO 22
IS 2
A1 Anneka Tomlinson
A1 Orestis Efthimiou
A1 Katharine Boaden
A1 Emma New
A1 Sarah Mather
A1 Georgia Salanti
A1 Hissei Imai
A1 Yusuke Ogawa
A1 Aran Tajika
A1 Sanae Kishimoto
A1 Sino Kikuchi
A1 Astrid Chevance
A1 Toshi A Furukawa
A1 Andrea Cipriani
YR 2019
UL http://mentalhealth.bmj.com//content/22/2/61.abstract
AB Introduction We have recently compared all second-generation as well as selected first-generation antidepressants in terms of efficacy and acceptability in the acute treatment of major depression. Here we present a protocol for a network meta-analysis aimed at extending these results, updating the evidence base and comparing all second-generation as well as selected first-generation antidepressants in terms of specific adverse events and tolerability in the acute treatment of major depression in adults.Methods and analysis We will include all double-blind randomised controlled trials comparing one active drug with another or with placebo in the acute treatment major depression in adults. We will compare the following active agents: agomelatine, amitriptyline, bupropion, citalopram, clomipramine, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, levomilnacipran, milnacipran, mirtazapine, nefazodone, paroxetine, reboxetine, sertraline, trazodone, venlafaxine, vilazodone and vortioxetine. The main outcomes will include the total number of patients experiencing specific adverse events; experiencing serious adverse events; and experiencing at least one adverse event. Published and unpublished studies will be retrieved through relevant database searches, trial registries and websites; reference selection and data extraction will be completed by at least two independent reviewers. For each outcome we will undertake a network meta-analysis to synthesise all evidence. We will use local and global methods to evaluate consistency. We will perform all analyses in R. We will assess the quality of evidence contributing to network estimates with the Confidence in Network Meta-Analysis web application.Discussion This work will provide an in- depth analysis and an insight into the specific adverse events of individual antidepressants.Ethics and dissemination This review does not require ethical approval.PROSPERO registration number CRD42019128141.